PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 105 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $39,544 | -13.0% | 17,893 | 0.0% | 0.00% | – |
| Q1 2023 | $45,448 | +35.8% | 17,893 | 0.0% | 0.00% | – |
| Q4 2022 | $33,460 | -27.3% | 17,893 | 0.0% | 0.00% | – |
| Q3 2022 | $46,000 | +17.9% | 17,893 | -10.9% | 0.00% | – |
| Q2 2022 | $39,000 | -90.4% | 20,078 | -85.4% | 0.00% | – |
| Q1 2022 | $407,000 | -33.9% | 137,094 | -0.1% | 0.00% | – |
| Q4 2021 | $616,000 | -9.7% | 137,251 | -2.1% | 0.00% | – |
| Q3 2021 | $682,000 | -21.5% | 140,159 | +10.0% | 0.00% | – |
| Q2 2021 | $869,000 | -5.5% | 127,447 | -2.2% | 0.00% | – |
| Q1 2021 | $920,000 | +11.5% | 130,283 | -1.2% | 0.00% | – |
| Q4 2020 | $825,000 | +14.4% | 131,851 | -1.0% | 0.00% | – |
| Q3 2020 | $721,000 | -3.6% | 133,222 | -7.1% | 0.00% | – |
| Q2 2020 | $748,000 | +97.4% | 143,367 | +19.1% | 0.00% | – |
| Q1 2020 | $379,000 | -22.0% | 120,384 | -0.2% | 0.00% | – |
| Q4 2019 | $486,000 | 0.0% | 120,605 | +7.2% | 0.00% | – |
| Q3 2019 | $486,000 | +13.0% | 112,525 | +4.4% | 0.00% | – |
| Q2 2019 | $430,000 | -43.7% | 107,819 | -24.3% | 0.00% | – |
| Q1 2019 | $764,000 | +7.6% | 142,495 | +3.0% | 0.00% | – |
| Q4 2018 | $710,000 | -46.3% | 138,282 | +1.4% | 0.00% | – |
| Q3 2018 | $1,323,000 | +0.5% | 136,376 | +5.7% | 0.00% | – |
| Q2 2018 | $1,316,000 | -13.5% | 129,044 | +10.2% | 0.00% | – |
| Q1 2018 | $1,522,000 | -50.2% | 117,064 | -31.5% | 0.00% | -100.0% |
| Q4 2017 | $3,058,000 | -29.6% | 170,849 | -1.3% | 0.00% | 0.0% |
| Q3 2017 | $4,345,000 | +4.5% | 173,102 | +0.3% | 0.00% | 0.0% |
| Q2 2017 | $4,157,000 | +156.9% | 172,499 | +105.2% | 0.00% | – |
| Q1 2017 | $1,618,000 | +47.0% | 84,045 | +17.5% | 0.00% | – |
| Q4 2016 | $1,101,000 | +28.5% | 71,540 | +8.6% | 0.00% | – |
| Q3 2016 | $857,000 | +36.5% | 65,900 | +46.0% | 0.00% | – |
| Q2 2016 | $628,000 | +2.1% | 45,140 | +11.4% | 0.00% | – |
| Q1 2016 | $615,000 | -20.4% | 40,524 | -0.6% | 0.00% | – |
| Q4 2015 | $773,000 | -82.3% | 40,760 | -82.3% | 0.00% | -100.0% |
| Q3 2015 | $4,365,000 | -28.0% | 229,742 | -2.3% | 0.00% | -50.0% |
| Q2 2015 | $6,059,000 | +35.3% | 235,170 | +64.2% | 0.00% | +100.0% |
| Q1 2015 | $4,477,000 | +28.6% | 143,221 | +58.6% | 0.00% | 0.0% |
| Q4 2014 | $3,482,000 | – | 90,326 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |